Fate Therapeutics (FATE) Competitors $0.85 -0.03 (-3.66%) Closing price 03/28/2025 04:00 PM EasternExtended Trading$0.87 +0.02 (+2.08%) As of 03/28/2025 07:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock FATE vs. SIGA, ERAS, HUMA, SNDL, PRTC, UPB, RNAC, KMDA, TRDA, and ETONShould you be buying Fate Therapeutics stock or one of its competitors? The main competitors of Fate Therapeutics include SIGA Technologies (SIGA), Erasca (ERAS), Humacyte (HUMA), SNDL (SNDL), PureTech Health (PRTC), Upstream Bio (UPB), Cartesian Therapeutics (RNAC), Kamada (KMDA), Entrada Therapeutics (TRDA), and Eton Pharmaceuticals (ETON). These companies are all part of the "pharmaceutical products" industry. Fate Therapeutics vs. SIGA Technologies Erasca Humacyte SNDL PureTech Health Upstream Bio Cartesian Therapeutics Kamada Entrada Therapeutics Eton Pharmaceuticals Fate Therapeutics (NASDAQ:FATE) and SIGA Technologies (NASDAQ:SIGA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, community ranking, valuation, risk, earnings, profitability, media sentiment and institutional ownership. Do analysts rate FATE or SIGA? Fate Therapeutics presently has a consensus target price of $5.43, indicating a potential upside of 539.18%. Given Fate Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Fate Therapeutics is more favorable than SIGA Technologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Fate Therapeutics 0 Sell rating(s) 7 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.22SIGA Technologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the MarketBeat Community favor FATE or SIGA? Fate Therapeutics received 475 more outperform votes than SIGA Technologies when rated by MarketBeat users. Likewise, 67.51% of users gave Fate Therapeutics an outperform vote while only 23.81% of users gave SIGA Technologies an outperform vote. CompanyUnderperformOutperformFate TherapeuticsOutperform Votes48067.51% Underperform Votes23132.49% SIGA TechnologiesOutperform Votes523.81% Underperform Votes1676.19% Does the media refer more to FATE or SIGA? In the previous week, SIGA Technologies had 2 more articles in the media than Fate Therapeutics. MarketBeat recorded 3 mentions for SIGA Technologies and 1 mentions for Fate Therapeutics. SIGA Technologies' average media sentiment score of 1.53 beat Fate Therapeutics' score of 1.44 indicating that SIGA Technologies is being referred to more favorably in the news media. Company Overall Sentiment Fate Therapeutics Positive SIGA Technologies Very Positive Which has more volatility and risk, FATE or SIGA? Fate Therapeutics has a beta of 2.26, indicating that its stock price is 126% more volatile than the S&P 500. Comparatively, SIGA Technologies has a beta of 0.98, indicating that its stock price is 2% less volatile than the S&P 500. Is FATE or SIGA more profitable? SIGA Technologies has a net margin of 49.33% compared to Fate Therapeutics' net margin of -1,325.43%. SIGA Technologies' return on equity of 49.06% beat Fate Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Fate Therapeutics-1,325.43% -45.88% -33.95% SIGA Technologies 49.33%49.06%38.72% Do institutionals and insiders believe in FATE or SIGA? 97.5% of Fate Therapeutics shares are owned by institutional investors. Comparatively, 55.4% of SIGA Technologies shares are owned by institutional investors. 5.0% of Fate Therapeutics shares are owned by company insiders. Comparatively, 1.5% of SIGA Technologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has better earnings & valuation, FATE or SIGA? SIGA Technologies has higher revenue and earnings than Fate Therapeutics. Fate Therapeutics is trading at a lower price-to-earnings ratio than SIGA Technologies, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFate Therapeutics$13.63M7.14-$160.93M-$1.64-0.52SIGA Technologies$138.72M2.86$68.07M$0.826.77 SummaryFate Therapeutics and SIGA Technologies tied by winning 9 of the 18 factors compared between the two stocks. Remove Ads Get Fate Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FATE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FATE vs. The Competition Export to ExcelMetricFate TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$97.33M$3.03B$5.63B$7.84BDividend YieldN/A1.54%4.59%4.01%P/E Ratio-0.5128.9323.3518.67Price / Sales7.14429.55387.8490.66Price / CashN/A168.6838.1734.64Price / Book0.233.926.894.23Net Income-$160.93M-$71.95M$3.20B$247.15M7 Day Performance-7.07%-5.55%-2.99%-2.18%1 Month Performance-24.17%-11.96%1.63%-5.68%1 Year Performance-88.43%-27.81%9.45%-0.74% Fate Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FATEFate Therapeutics3.8299 of 5 stars$0.85-3.7%$5.43+539.2%-88.4%$97.33M$13.63M-0.51550Positive NewsSIGASIGA Technologies2.5472 of 5 stars$5.98+6.6%N/A-35.2%$427.19M$138.72M4.9840Analyst RevisionPositive NewsERASErasca3.6253 of 5 stars$1.49-2.6%$4.80+222.1%-26.2%$421.26MN/A-1.80120Analyst ForecastNews CoverageHUMAHumacyte2.1447 of 5 stars$3.32flat$13.71+313.1%-37.0%$417.85M$1.57M-2.48150Earnings ReportUpcoming EarningsAnalyst ForecastNews CoverageGap UpSNDLSNDL3.5445 of 5 stars$1.59+0.6%$3.63+128.0%-27.7%$417.81M$920.45M-5.13580PRTCPureTech Health1.5216 of 5 stars$17.30+3.5%$45.00+160.1%-32.5%$415.51M$3.33M0.00100Gap UpUPBUpstream BioN/A$7.70+1.0%$56.50+633.8%N/A$413.04M$2.37M0.0038News CoveragePositive NewsRNACCartesian Therapeutics2.1619 of 5 stars$15.94-0.7%$42.14+164.4%-25.4%$412.96M$38.91M-0.3064KMDAKamada3.5271 of 5 stars$7.10+5.7%$14.67+106.6%+20.3%$408.11M$160.95M25.36360Analyst DowngradeShort Interest ↑High Trading VolumeTRDAEntrada Therapeutics2.794 of 5 stars$10.80+3.0%$25.67+137.7%-32.5%$406.03M$210.78M6.79110ETONEton Pharmaceuticals2.7516 of 5 stars$14.79+4.0%$27.67+87.1%+247.2%$396.64M$39.01M-67.2320Short Interest ↓ Remove Ads Related Companies and Tools Related Companies SIGA Technologies Alternatives Erasca Alternatives Humacyte Alternatives SNDL Alternatives PureTech Health Alternatives Upstream Bio Alternatives Cartesian Therapeutics Alternatives Kamada Alternatives Entrada Therapeutics Alternatives Eton Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FATE) was last updated on 3/29/2025 by MarketBeat.com Staff From Our PartnersA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fate Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Fate Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy FATE Stock Free FATE Stock Alerts